The market is segmented based on
閉経後膣萎縮症治療の世界市場、治療タイプ別（エストロゲン系薬剤、非エストロゲン系薬剤、その他）、薬剤形態別（膣ジェル、クリーム、タブレット、その他）、投与経路別（経口、膣内、その他）、エンドユーザー別（病院、在宅ケア、専門クリニック、その他）、流通チャネル別（病院薬局、オンライン薬局、小売薬局）– 2030年までの業界動向と予測。
.
The Global Postmenopausal Vaginal Atrophy Treatment Market size was valued at USD 2.52 USD Billion in 2022.
The Global Postmenopausal Vaginal Atrophy Treatment Market is projected to grow at a CAGR of 7.5% during the forecast period of 2023 to 2030.
The major players operating in the market include ,Key players operating in the postmenopausal vaginal atrophy treatment market include:Pfizer Inc ,Mylan N.V. ,Novartis AG ,Hikma Pharmaceuticals plc ,Aurobindo Pharma ,AbbVie Inc. ,Melinta TherapeuticsInc ,Bristol-Myers Squibb Company ,GSK plc. ,Bayer AG ,Lupin ,Perrigo Company plc ,BionovoInc. ,TherapeuticsMDInc. ,EndoceuticsInc ,Upsher-Smith LaboratoriesLLC ,Ligand Pharmaceuticals Incorporated ,Pantarhei Bioscience .
Corporate Email ID Only (Avoid Using Generic mail ID such as Gmail)
Consent Preferences
We use cookies to improve your experience We use cookies to deliver the best possible experience on our website. To learn more, visit our Privacy Policy. By continuing to use this site, or closing this box, you consent to our use of cookies. Cookie Notice.
The data presented is for visualization purposes only and may not reflect actual results.